Literature DB >> 33476813

The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies.

Giacomo Ramponi1, Marco Folci1, Maria De Santis1, Jan G M C Damoiseaux2, Carlo Selmi3, Enrico Brunetta1.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies, predominantly IgG, involved in the pathogenesis of several autoimmune disorders, detected either through indirect immunofluorescence or enzyme-linked immunosorbent assay. By means of indirect immunofluorescence, the main patterns are C-ANCA (cytoplasmic) and P-ANCA (perinuclear), while proteinase 3 (PR3) and myeloperoxidase (MPO) represent the main autoantigens in granulomatosis with polyangiitis and microscopic polyangiitis, both belonging to the family of ANCA-associated vasculitis (AAV). While several experiments established the pathogenicity of MPO-ANCA, evidence remains elusive for PR3-ANCA and an additional target antigen, i.e. LAMP2, has been postulated with specific clinical relevance. The presence of a subset of AAV without ANCA may be explained by the presence of further target antigens or the presence of molecules in blood which make ANCA undetectable. A rise in ANCA titers is not necessarily predictive of a flare of disease in AAV if not accompanied by clinical manifestations. ANCA may develop through variable mechanisms, such as autoantigen complementarity, apoptosis impairment, neutrophil extracellular traps dysfunction and molecular mimicry. We will provide herein a comprehensive review of the available evidence on the biological mechanisms, pathogenetic role, and clinical implications of ANCA testing and disease management. Further, we will address the remaining open challenges in the field, including the role of ANCA in inflammatory bowel disease and in cocaine-induced vasculitis.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Eosinophil; Granulomatous polyangiits; HLA; Small-vessel vasculitis; Tolerance breakdown

Mesh:

Substances:

Year:  2021        PMID: 33476813     DOI: 10.1016/j.autrev.2021.102759

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

1.  Identification of bacteria by poly-aromatic hydrocarbon biosensors.

Authors:  Yaniv Shlosberg; Yair Farber; Salah Hasson; Valery Bulatov; Israel Schechter
Journal:  Anal Bioanal Chem       Date:  2022-02-07       Impact factor: 4.142

2.  A case of smoldering antineutrophil cytoplasmic antibody-associated vasculitis development during the course of primary Sjögren's syndrome.

Authors:  Yoichi Iwafuchi; Tetsuo Morioka; Yuko Oyama; Ichiei Narita
Journal:  CEN Case Rep       Date:  2021-11-17

3.  Gene polymorphisms in ULK1 and PIK3CA are associated with the risk of microscopic polyangiitis in the Guangxi Zhuang Autonomous Region in China.

Authors:  Yan Zhu; Jinlan Rao; Jingsi Wei; Liu Liu; Shanshan Huang; Jingjing Lan; Chao Xue; Wei Li
Journal:  PeerJ       Date:  2021-11-09       Impact factor: 2.984

4.  Biomarkers of Endothelial Damage in Distinct Phases of Multisystem Inflammatory Syndrome in Children.

Authors:  Monica Gelzo; Antonietta Giannattasio; Marco Maglione; Stefania Muzzica; Carolina D'Anna; Filippo Scialò; Thaililja Gagliardo; Michela Grieco; Vincenzo Tipo; Giuseppe Castaldo
Journal:  Metabolites       Date:  2022-07-24

Review 5.  Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature.

Authors:  Inge C Van Gool; Jesper Kers; Jaap A Bakker; Joris I Rotmans; Y K Onno Teng; Martijn P Bauer
Journal:  Clin Rheumatol       Date:  2022-06-23       Impact factor: 3.650

6.  Serum ANCA and Overall Mortality: A 10-Year Retrospective Cohort Study on 1,024 Italian Subjects.

Authors:  Enrico Brunetta; Giacomo Ramponi; Marco Folci; Maria De Santis; Emanuela Morenghi; Elena Vanni; Elena Bredi; Raffaello Furlan; Claudio Angelini; Carlo Selmi
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.